Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

Detailed price information for Starbucks Corp (SBUX-Q) from The Globe and Mail including charting and trades.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has recurred in patients who had ...

Major indices were in the green earlier on Wednesday as traders digested more bank earnings and another key inflation report.

JP Morgan Chase & Co (NYSE:JPM) shares are trending on Wednesday. Here's a look at what's going on.

By Colin Kellaher Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.